申请人:Schering Aktiengesellschaft
公开号:US04585771A1
公开(公告)日:1986-04-29
Imidazole derivatives of Formula I ##STR1## wherein AR.sub.1 and AR.sub.2 each independently represent phenyl optionally substituted by halogen atoms, alkyl groups, or alkoxy groups, R.sub.1 is pyrrolyl, indolyl, imidazolyl, or thiazolyl, all of which are optionally substituted by lower alkyl, free or esterified carboxy or carboxyalkyl groups, benzyl, or benezenesulfonyl; and R.sub.2 is hydrogen, lower alkyl, haloalkyl, or a methylene, dimethylene, trimethylene, or tetramethylene group linked to the nitrogen atom of R.sub.1, and the physiologically acceptable salts thereof with acids, and when R.sub.1 is substituted by carboxy, also the physiologically acceptable salts thereof with bases, are pharmacologically effective compounds, e.g., as antiinflammatories.
化合物I式的咪唑衍生物 ##STR1## 其中AR.sub.1和AR.sub.2各自独立地表示苯基,可选择地被卤素原子,烷基或烷氧基取代,R.sub.1是吡咯基,吲哚基,咪唑基或噻唑基,均可选择地被较低的烷基,自由或酯化的羧基或羧基烷基取代,苯甲基或苯磺酰基取代; R.sub.2是氢,较低的烷基,卤代烷基或与R.sub.1的氮原子连接的亚甲基,二亚甲基,三亚甲基或四亚甲基基团,以及它们与酸的生理上可接受的盐,当R.sub.1被羧基取代时,还包括与碱的生理上可接受的盐,是药理学上有效的化合物,例如,作为抗炎剂。